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2-Methoxyoestradiol (2-MeOE2) is an endogenous oestrogen metabolite that inhibits the proliferation of cancer cells in vitro, and it is
also antiangiogenic. In vivo 2-MeOE2, when administered at relatively high doses, inhibits the growth of tumours derived from breast
cancer cells, sarcomas and melanomas. Sulphamoylated derivatives of 2-MeOE2 are more potent inhibitors of in vitro breast cancer
cell growth than 2-MeOE2. In the present study, we have compared the pharmacokinetic profiles and metabolism of 2-MeOE2 and
its sulphamoylated derivative, 2-methoxyoestradiol-bis-sulphamate (2-MeOE2bisMATE), in adult female rats. Their ability to inhibit
tumour growth was compared in nude mice bearing xenografts derived from MDA-MB-435 (oestrogen receptor negative)
melanoma cancer cells. After a single oral 10mgkg
 1 dose of 2-MeOE2bisMATE, significant concentrations of this compound were
still detectable at 24h. In contrast, no 2-MeOE2 or metabolites were detected in plasma at any time after a 10mgkg
 1 oral dose.
Thus, the bioavailability of 2-MeOE2 is very low, whereas for 2-MeOE2bisMATE it was 85%. No significant metabolites of
2-MeOE2bisMATE were detected in plasma after oral or intravenous dosing, showing that this drug is resistant to metabolism. In the
tumour efficacy model, oral administration of 2-MeOE2bisMATE, at 20mgkg
 1day
 1 daily for 28 days, almost completely inhibited
tumour growth. Inhibition of tumour growth was maintained for a further 28 days after the cessation of dosing. At this dose level,
2-MeOE2 did not inhibit tumour growth. The resistance to metabolism shown by 2-MeOE2bisMATE and its ability to inhibit tumour
growth in vivo suggest that this compound should have considerable potential for development as a novel anticancer drug.
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2-Methoxyoestradiol (2-MeOE2, Figure 1, 1), a metabolite of
oestradiol, is generated in vivo by catechol-O-methyl transferase,
an enzyme which is expressed in a plethora of mammalian tissues
including the liver, kidney, brain and red blood cells (Mannisto
and Kaakkola, 1999). 2-Methoxyoestradiol has been shown to
inhibit the growth of ERþ and ER  breast cancer cell lines and
HeLa cells (Seegers et al, 1989; Lottering et al, 1992; Raobaikady
et al, 2003). It does not stimulate uterotropic growth, and has a low
binding affinity for the oestrogen receptor (Ball and Knuppen,
1980; Merriam et al, 1980), and therefore it must act via an
oestrogen receptor-independent mechanism (LaVallee et al, 2002).
It also inhibits the in vivo growth of xenografts derived from
human MDA-MB-435 melanoma cells, Meth A sarcomas, B16
melanomas and the multiple myeloma cell line KAS-6/1 in
immunodeficient mice (Fotsis et al, 1994; Klauber et al, 1997;
Dingli et al, 2002). However, comparatively high oral or
intraperitoneal doses of 75 and 150mgkg
 1day
 1, respectively,
of 2-MeOE2 were necessary to reduce the growth of melanoma or
myeloma tumours (Klauber et al, 1997; Dingli et al, 2002). The
relatively high doses of 2-MeOE2 required to inhibit tumour
growth in vivo in the mouse may be a corollary of poor
gastrointestinal absorption and/or rapid metabolic deactivation
of the agent, although this remains to be experimentally
determined.
In addition to inhibiting the proliferation of cancer cells,
2-MeOE2 also possesses antiangiogenic properties (Fotsis et al,
1994). Inhibition of human umbilical vein endothelial cell
(HUVEC) growth is used as a predictive assay of a drug’s
antiangiogenic potential. The sulphamoylated product of
2-MeOE2, 2-methoxyoestradiol-bis-sulphamate (2-MeOE2bis-
MATE, Figure 1, 2), was 60-fold more potent in an in vitro
HUVEC growth-inhibition assay (Newman et al, 2004). 2-
Methoxyoestradiol-bis-sulphamate has also been shown to inhibit
neo-vascularisation in vivo in the mouse Matrigel plug model of
angiogenesis (Chander et al, 2003).
2-MeOE2bisMATE is a derivative of oestrone-3-O-sulphamate
(EMATE, Figure 1, 4) which was originally developed as a steroid
sulphatase (STS) inhibitor (Purohit et al, 1998). Unexpectedly,
EMATE proved to be a potent oestrogen on oral application in rats
(Elger et al, 1995). The observed oestrogenicity of oestrogen
sulphamates, such as EMATE, is thought to be a consequence of
their sequestration into red blood cells (RBCs) and slow release of
the oestrogen moiety into plasma (Elger et al, 1998). It is
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sconceivable that, similarly, the sulphamoylation of 2-MeOE2, and
the subsequent uptake of the ester into erythrocytes, may reduce
the first pass metabolism of the agent and thus enhance its oral
bioavailability. To investigate this postulate we compared the
pharmacokinetics of 2-MeOE2bisMATE and 2-MeOE2 following
administration of a single oral or intravenous dose in rats.
In addition, as part of the pharmacokinetic study, we also
examined the metabolism of these two compounds in vivo.A s
sulphamoylated steroids can act as STS inhibitors, the ability of
2-MeOE2bisMATE to inhibit the in vivo activity of this enzyme was
also examined (Reed et al, 1996). To compare the abilities of
2-MeOE2 and 2-MeOE2bisMATE to inhibit tumour growth in vivo,
their effects on the growth of xenografts derived from MDA-MB-
435 (ER ) human melanoma cells were also examined. This cell
line was chosen for in vivo studies, as it had previously been used
to test the efficacy of 2-MeOE2 (Klauber et al, 1997). Since the
present study was initiated, it has been revealed that the MDA-MB-
435 cell line is not derived from a breast carcinoma, but probably
originates from a melanoma (Ellison et al, 2002). However, as this
cell line is highly metastatic and ER , it remains a good model for
testing agents which should be active against a wide range of
hormone-independent cancers.
MATERIALS AND METHODS
Chemicals and reagents
The following reagents were purchased from the suppliers listed:
high-performance liquid chromatography (HPLC) grade methanol,
diethyl ether (Fisher Scientific UK Limited, Loughborough,
Leicestershire, UK); Halothane Astra Zeneca, Cheshire, UK);
propylene glycol, ammonium sulphate, sodium azide, tetrahydro-
furan (THF) (Sigma-Aldrich Comp. Ltd, Poole, Dorset, UK); 17a-
epitestosterone (Steraloids, Newport, RI, USA); [6,7-
3H] oestrone
sulphate (43-50Cimmol
 1, Perkin-Elmer, Boston, MA, USA). 2-
methoxyoestrone (2-MeOE1, Figure 1, 5), 2-MeOE2, 2-MeOE2bis-
MATE, 2-MeOE2-3S (Figure 1, 3), 2-methoxyoestradiol-3-sulpha-
mate (2-MeOE2-3MATE, Figure 1, 6) and 2-methoxyoestradiol-17-
sulphamate (2-MeOE2-17MATE, Figure 1, 7) were synthesised
from oestrone. All new compounds exhibited spectroscopic and
analytical data in accordance with their structure. Full details of
their synthesis will be reported elsewhere.
In vivo pharmacokinetic and metabolism studies
Female Wistar (155–165g) rats were purchased from Charles
River UK Ltd (Margate, Kent, UK) and housed in a dedicated
animal facility. Rats received RM1 rodent maintenance diet (SDS,
Kent, UK), water ad libitum, and were maintained in positive
pressure isolators under a 12h light–dark cycle. These experi-
ments were carried out under conditions that complied with
institutional requirements. Rats received 2-MeOE2 or 2-MeOE2-
bisMATE (10mgkg
 1, oral or intravenous), with control animals
receiving vehicle only (propylene glycol: THF, 9:1 vv
 1). There
were two reasons for selecting 10mgkg
 1 for both oral and
intravenous dosing. Firstly, a single dose of EMATE administered
by these routes has been shown to inhibit rat liver sulphatase by at
least 99% (Purohit et al, 1995). Secondly, administration of this
dose was found to elicit sufficiently high levels of the agents for
their detection in plasma. Rats were subjected to terminal
anaesthesia (Halothane) and blood removed by cardiac puncture
at 5, 15 and 30min and 1, 3, 8 and 24h after intravenous
administration, and 15 and 30min and 1, 3, 8, 24 and 48h
following oral administration of 2-MeOE2 or 2-MeOE2bisMATE.
Plasma was prepared from whole blood by centrifugation (2800g,
41C, 15min). Plasma (0.5ml) was extracted with diethyl ether
(4ml) and frozen in a methanol:solid carbon dioxide mixture.
17a-Epitestosterone (28mgml
 1) was used as an internal standard
after purification by HPLC. The organic phase was decanted to a
fresh tube and evaporated to dryness under a stream of air at room
temperature. The extraction efficiencies for 2-MeOE2 and 2-
MeOE2bisMATE from plasma were 7175 and 7574% (n¼6),
respectively. The residues were stored at  201C until analysis by
HPLC.
HPLC analysis
2-MeOE2bisMATE was separated from its putative metabolites, 2-
MeOE2, 2-MeOE2-3MATE and 2-MeOE2-17MATE, using a mod-
ified version of a reversed-phase HPLC method described
previously (Hildago Aragones et al, 1996). An Agilent 1100
(Cheshire, UK) autosampler, photodiode array detector and
solvent delivery system were used. The agents were separated
from endogenous plasma components by an isocratic mobile phase
consisting of 58% methanol in 0.02 M ammonium sulphate. Sodium
azide (1mM) was added to the mobile phase in order to decrease
microbial growth. Extracted samples were reconstituted in mobile
phase and aliquots of 100ml were injected on to a C3-phenyl
column (250 5mm, 5mm) purchased from Phenomenex (Che-
shire, UK). 2-Methoxyoestradiol-bis-sulphamate, 2-MeOE2 and
their metabolites were analysed with a photodiode array detector
with detection at 285nm. The method was validated by spiking
plasma with 2-MeOE2bisMATE (960ngml
 1). The inter-day and
intra-day coefficients of variation were 8.2% (n¼6) and 3.8%
(n¼6), respectively. Quantification was achieved by spiking
plasma with 2-MeOE2bisMATE and the internal standard 17a-
epitestosterone, extraction with diethyl ether and subsequent
analysis by HPLC. Plasma calibration curves were found to be
linear from 40 to 9000ngml
 1. The limits of detection (LODs) and
quantification of 2-MeOE2bisMATE in plasma were 11 and
40ngml
 1, respectively.
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Figure 1 Structures: compound 1, 2-MeOE2; compound 2, 2-MeO-
E2bisMATE; compound 3, 2-MeOE2-3S; compound 4, EMATE; compound
5, 2-MeOE1; compound 6, 2-MeOE2-3MATE; compound 7, 2-MeOE2-
17MATE.
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sPharmacokinetic analysis
Pharmacokinetic parameters were calculated using WinNonlin
software (Pharsight Corporation, Mountview, CA, USA). The area
under the curve (AUC) was calculated using the linear trapezoidal
method, with extrapolation of the terminal phase to infinity. Other
parameters calculated were: distribution and elimination rate
constants (a and b); total body clearance (Cl)¼dose/AUC; volume
of distribution (Vd)¼Cl/b; distribution half-life (t1/2a)¼0.693/a;
elimination half-life (t1/2b)¼0.693/b; bioavailability (%
F¼(AUCoral/AUCi.v) 100).
Liver oestrone sulphatase activity
Livers were obtained from animals administered with 2-MeOE2 or
2-MeOE2bisMATE either orally or intravenously, to assess their
effects on steroid sulphatase activity. Steroid sulphatase activity
was measured as described previously (Purohit et al, 1995).
In vivo inhibition of tumour growth
To compare the anticancer effects of 2-MeOE2 and 2-MeOE2bis-
MATE, xenografts derived from MDA-MB-435 (ER ) human
melanoma cells were transplanted into female nude mice with
eight mice per group. These studies were carried out by Anti-
Cancer Inc. (San Diego, CA, USA). Treatment was initiated when
tumour volumes reached 100–200mm
3. Drugs were dissolved in a
minimum volume of THF, diluted with propylene glycol and
administered at 20mgkg
 1, oral, daily for 28 days. The length (l)
and width (w) of tumours was measured at weekly intervals, from
which the tumour volumes were calculated using the formula
(l w
2/2). Monitoring of tumour volumes continued for a further
28-day period after the end of drug administration. The body
masses of control and treated animals were also measured at
weekly intervals as an indicator of any toxicity that might be
associated with the use of these drugs.
Statistics
Student’s t-test was used to assess the significance of differences in
tumour volumes between control and treated animals.
RESULTS
HPLC analysis
A reproducible, robust and sensitive analytical method was
developed for the detection of 2-MeOE2 and 2-MeOE2bisMATE
in plasma. The method facilitated separation of these agents from
the putative metabolites 2-MeOE1, 2-MeOE2-17MATE and 2-
MeOE2-3MATE, the internal standard, 17a-epitestosterone, and
endogenous plasma components.
Pharmacokinetics of 2-MeOE2 and 2-MeOE2bisMATE
In order to compare the pharmacokinetics of 2-MeOE2 and 2-
MeOE2bisMATE, rats were administered with either a single
intravenous or oral dose of the agents. Using the HPLC analytical
method developed, it was possible to detect both compounds in
plasma after intravenous administration (Figure 2B,C), but only 2-
MeOE2bisMATE was detected after oral administration (Figure
2E,F). The identities of these agents were corroborated by
electrospray ionisation liquid chromatography-mass spectrometry
in the selected ion mode (results not shown). When 2-MeOE2 was
given to rats as an intravenous bolus, the agent was found to be
rapidly removed from the plasma (Figure 3A) and was below the
LOD (11ngml
 1) 1h after administration of the dose. Conse-
quently, it was not possible to determine the pharmacokinetic
parameters for 2-MeOE2. In contrast, when 2-MeOE2bisMATE was
administered as an intravenous bolus, the parent compound was
quantifiable in plasma 8h after administration of the agent
(1.5270.10mgml
 1), although it was not detectable by 24h. The
decrease in plasma concentration of 2-MeOE2bisMATE followed a
biexponential pattern with an initial distribution half-life (t1/2a)o f
0.2270.10h and a terminal half-life (t1/2b) of 8.5071.16h. The
area under the plasma concentration–time curve (AUC) was
513.997153.88hmgml
 1. Pharmacokinetic parameters after oral
administration were calculated using an extravascular noncom-
partmental model. Maximum levels of 2-MeOE2bisMATE in
plasma (Cmax¼3.9070.25mgml
 1) were reached 3h after oral
administration of the agent (Figure 3B and Table 1) with
0.5370.04mgml
 1 still detectable after 24h. A terminal plasma
half-life of 6.5171.09h with an AUC of 388.84728.84hmgml
 1
was achieved. The bioavailability for 2-MeOE2bisMATE based on
AUC after intravenous or oral administration was 85.19716.09%.
The putative metabolites of 2-MeOE2bisMATE, 2-MeOE2-
17MATE, 2-MeOE2-3MATE and 2-MeOE2 were not above the
LOD in plasma.
Inhibition of liver sulphatase
Hepatic sulphatase activity was inhibited by 99.570.5% compared
with the activity measured in control animals, following admin-
istration of a single oral or intravenous dose of 2-MeOE2bisMATE.
This level of inhibition of sulphatase activity was maintained for
48h following administration of 2-MeOE2bisMATE. 2-Methox-
yoestradiol did not affect rat liver sulphatase activity (data not
shown).
In vivo inhibition of tumour growth
To compare the effects of 2-MeOE2 and 2-MeOE2bisMATE on in
vivo tumour growth in nude mice that had been inoculated with
xenografts derived from MDA-MB-435 human melanoma cells,
animals were treated with drugs (20mgkg
 1, oral) daily for 28
days (Figure 4). At this dose, 2-MeOE2 had no significant effect on
tumour growth during the treatment or post-dosing periods. In
contrast, by week 2 of dosing, the tumour volumes of mice
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Figure 2 HPLCs of diethyl ether plasma extracts. Plasma was prepared
from whole blood following administration of intravenous (A) propylene
glycol, (B) 2-MeOE2, (C) 2-MeOE2bisMATE or oral, (D) propylene glycol,
(E) 2-MeOE2 and (F) 2-MeOE2bisMATE. The blood was removed from
animals 0.25 and 3h after intravenous and p.o. dosing, respectively. The
identities of 2-MeOE2, 2-MeOE2bisMATE and 17a-epitestosterone
(internal standard) as being peaks 1, 2 and 3, respectively, were
corroborated by co-elution with authentic standards and liquid chromato-
graphy-mass spectrometry. For details of extraction and HPLC analysis, see
‘Materials and Methods’. The peak eluting at 3.9min was an endogenous
plasma component.
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sreceiving 2-MeOE2bisMATE were significantly smaller (Po0.05)
than those of the control group. Tumour volumes for mice treated
with 2-MeOE2bisMATE then remained significantly smaller
(Po0.01) for the remaining period of the study. At 4 weeks, at
the end of the dosing period, the mean tumour volumes in mice
receiving 2-MeOE2bisMATE were 14% of that of tumour volume in
the control animals. This difference (86%) in tumour volumes
between the two groups was maintained for a further 4 weeks after
the cessation of drug administration. No significant differences in
the change in weights between the control and treated animals
were detected during the treatment or post-dosing periods
(Figure 5).
DISCUSSION
The sulphamoylated oestrogen derivative 2-MeOE2bisMATE has
previously been shown to be a more potent inhibitor of cancer cell
proliferation than its parent compound, 2-MeOE2 (Raobaikady
et al, 2003). Furthermore, in in vitro models of angiogenesis, 2-
MeOE2bisMATE proved to be considerably more potent as an
inhibitor of angiogenesis than 2-MeOE2 (Newman et al, 2004). The
main finding to emerge from the present in vivo study goes some
way to offer an explanation for the enhanced potency of 2-
MeOE2bisMATE. In this study, the plasma concentrations of both
drugs were determined after oral or intravenous dosing, together
with an examination of the duration for which the compounds and
putative metabolites were detectable in plasma. After intravenous
administration of 2-MeOE2, the compound was rapidly cleared
from the plasma, suggesting metabolic removal. 2-Methoxyoestra-
diol eluded detection in plasma after its oral administration and,
by 1h after intravenous dosing, levels were below the LOD for the
assay. In contrast, significant concentrations of 2-MeOE2bisMATE
were detectable in plasma after its oral or intravenous adminis-
tration with 450ngml
 1 still being detectable at 24h after oral
dosing. Recently, a daily oral dose of 1000mg 2-MeOE2 was given
to 24 patients with advanced metastatic breast cancer (Sledge et al,
2002; Lakhani et al, 2003). It was shown that 2-MeOE2 was
metabolised to 2-MeOE1 and 2-MeOE2/2-MeOE1 glucuronide and
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Figure 3 Concentrations of 2-MeOE2 and 2-MeOE2bisMATE in rat
plasma following a single intravenous (A) or oral (B) bolus of drug
(10mgkg
 1) in THF/propylene glycol. The values shown are the means
7s.e.m. (n¼3). 2-Methoxyoestradiol was below the LOD (11ngml
 1)i n
plasma after oral administration. Where no error bars are shown, the
coefficient of variation is o10%.
Table 1 Summary of 2-MeOE2bisMATE pharmacokinetic data after
bolus intravenous or oral administration
PK parameters Intravenous Oral
Cmax (mgml
 1) 6.5570.92 3.9070.25
t1/2a (h) 0.2270.10 —
t1/2b (h) 8.5071.16 6.5171.09
AUC (hmgml
 1) 513.997153.88 388.84728.84
Vd (l) 0.2870.09 0.3570.02
Cl (lh
 1) 0.0570.01 0.03670.001
% F (bioavailability) — 85.19716.09
Values shown are mean7s.e.m. (n¼3).
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Figure 4 In vivo effect of 2-MeOE2 or 2-MeOE2bisMATE on the growth
of MDA-MB-435 (ER ) xenografts in nude mice. Vehicle (THF/propylene
glycol) or compounds were administered daily (20mgkg
 1, oral) for 28
days. Tumour volumes were monitored at weekly intervals for the duration
of drug administration and for a further 4-week period after the end of drug
administration (means7s.e.m., n¼8). Results are expressed as percentage
change in tumour volumes detected at weekly intervals. At this dose, 2-
MeOE2 had no significant effect on tumour growth during the treatment or
post-dosing periods. For 2-MeOE2bisMATE-treated animals, tumour
volumes were significantly smaller than those in control animals by week
2( Po0.05) and remained significantly smaller (Po0.01) for the rest of the
study period.
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ssulphate conjugates. Demethylated 2-MeOE1 (2-OHE1) has also
been measured in the urine of humans administered with [
3H]2-
MeOE2, although this metabolite could not be detected in plasma
(Longcope et al, 1980).
After intravenous administration of 2-MeOE2, its half-life in
plasma was approximately 14min. Pharmacokinetic studies in rats
indicated that 2-MeOE2bisMATE was detectable in plasma for up
to at least 24h after oral administration. The calculated bioavail-
ability for 2MeOE2bisMATE from the AUC was 85.2%. A possible
explanation for this finding may be that, initially, there is
sequestration of 2-MeOE2bisMATE into blood components,
possibly RBCs (unpublished data), or binding to plasma proteins,
resulting in high AUC orally. This may, in part, account for the
slow clearance rates and the high volume of distribution achieved
by both intravenous and oral administration. Nevertheless, it is
apparent that 2-MeOE2bisMATE has a higher level of bioavail-
ability after oral administration, compared with that of the non-
sulphamoylated 2-MeOE2.
Further evidence of the enhanced potency of 2-MeOE2bisMATE
compared with that of 2-MeOE2 was obtained from the in vivo
study carried out in nude mice bearing xenografts of MDA-MB-435
tumours. 2-Methoxyoestradiol had little effect on the growth of
these tumours. In contrast, for animals receiving 2-MeOE2bis-
MATE, tumour growth was almost completely inhibited for the 4-
week treatment period, and its growth-inhibiting effects were
maintained for 4 weeks after the cessation of dosing. It is evident
from the present study that 2-MeOE2bisMATE can inhibit in vivo
tumour growth. Further studies will be required to ascertain
whether it is acting by inhibition of angiogenesis or induction of
apoptosis or, as most likely, a combination of both mechanisms.
No decreases in body weights were detected in animals receiving
either 2-MeOE2 or 2-MeOE2bisMATE, indicating that, at the dose
tested, these compounds have little or no toxicity.
From these studies, it is evident that 2-MeOE2bisMATE is
resistant to metabolism in vivo, and this finding goes some way to
account for its enhanced potency compared with 2-MeOE2.I n
vivo, the C3 phenolic group and 17b hydroxyl group of 2-MeOE2
are likely to be subjected to rapid conjugation or oxidation, thus
reducing the potency of this compound as an anticancer and
antiangiogenic drug. Several derivatives of 2-MeOE2 have been
developed, such as 2-methoxymethyloestradiol and a series of 2-
methoxytetrane oestradiols, which are more potent inhibitors of in
vitro cancer cell proliferation than 2-MeOE2 itself (Bruggemeier
et al, 2001; Tinley et al, 2003). However, as these compounds retain
the C3/17b configuration of 2-MeOE2, it is unlikely that they will
prove to be more potent in vivo and will undergo the same route of
rapid inactivation.
EMATE was previously found to have a half-life of 4.5h in
plasma (Hildago Aragones et al, 1996), and this compares with the
much shorter half-life for unconjugated oestrogen of 20–30min
(Ruder et al, 1972). Like EMATE, 2-MeOE2bisMATE is a potent
steroid sulphatase inhibitor and, in the present study, liver
sulphatase was rapidly inactivated after its oral or intravenous
administration. Almost complete inhibition of steroid sulphatase
activity (499%) was achieved within 5 and 15min of intravenous
and oral dosing, respectively. Inhibition of steroid sulphatase
activity will prevent removal of the sulphamoyl group at the
C3 position, thus greatly prolonging the plasma, and presumably
tissue, concentrations of the active sulphamoylated drug.
The relatively high plasma concentrations of 2-MeOE2bisMATE
(up to 5mM) detected are within the range that has been shown to
inhibit cancer cell and HUVEC proliferation in vitro (Newman
et al, 2004). Thus, sulphamoylation of 2-MeOE2 yields a drug that
is resistant to in vivo metabolism. In vivo, its ability to inhibit STS
appears to block its de-sulphamoylation, ensuring that the
biologically active drug is available to exert its effects for a
prolonged period of time. The findings from in vitro studies that 2-
MeOE2bisMATE is more potent than 2-MeOE2, together with the
results of the in vivo studies showing no evidence of conversion to
2-MeOE2, indicate that it is not acting as a pro-drug for the
formation of 2-MeOE2.
There is currently considerable interest in exploring the
mechanisms by which 2-MeOE2 and its sulphamoylated derivates
act to inhibit cancer cell growth and angiogenesis. 2-Methoxyoes-
tradiol is an endogenous oestrogen metabolite, and it has been
suggested that it may be the body’s natural anticancer metabolite
(Zhu and Conney, 1998). This contention is supported by a
significant body of research carried out by Bradlow et al (1998),
who have convincingly demonstrated that production of 2-MeOE2
is increased in women at low risk of breast cancer. 2-
Methoxyoestradiol and its sulphamoylated derivatives are thought
to bind to the colchicine-binding site of tubulin, where they act to
alter microtubule dynamics, leading to activation of the intrinsic
apoptotic pathway via BCL-2 phosphorylation (D’Amato et al,
1994; MacCarthy-Morrogh et al, 2000). In addition, it is possible
that, like 2-MeOE2, the sulphamoylated derivatives will also act to
induce apoptosis via activation of the extrinsic apoptotic pathway,
which involves upregulation of death receptors, such as DR5
(LaVallee et al, 2003).
In vitro, 2-MeOE2 has been shown to inhibit the proliferation of
a wide range of cancer cells including those derived from the
breast, prostate, ovary, pancreas, lung and multiple myelomas. At
relatively high doses (75–150mgkg
 1), its efficacy in mouse
models against melanomas, Meth A sarcomas and multiple
myelomas has been demonstrated (Klauber et al, 1997; Dingli
et al, 2002). As shown in the present in vivo efficacy study at a dose
of 20mgkg
 1, while 2-MeOE2 was ineffective, 2-MeOE2bisMATE
almost completely blocked tumour growth. The identification of 2-
MeOE2bisMATE as a potent anticancer, antiangiogenic drug that is
orally available, yet resistant to metabolism, should make it a good
candidate for development for cancer therapy.
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and the results are expressed as the percentage change compared with
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